Silica-Lipid Hybrid (SLH) Versus Non-lipid Formulations for Optimising the Dose-Dependent Oral Absorption of Celecoxib
- 835 Downloads
To investigate the dose linearity of celecoxib (CEL) pharmacokinetics from various non-lipid and lipid-based formulations; to probe the mechanisms of CEL absorption from a nano-structured silica-lipid hybrid (SLH) microparticle dosage form.
Single-dose pharmacokinetic parameters of CEL were determined in fasted rats at dose levels of 5, 20 and 50 mg/kg in aqueous suspensions of pure CEL, Celebrex® and CEL-SLH microparticles formulated using medium-chain lipids (Miglyol 812 or Capmul MCM) and Aerosil® silica nanoparticles. An in vitro lipolysis model was used to characterise the dynamic solubilisation state of CEL under digesting conditions.
CEL-SLH formulations and Celebrex® consistently produced a 2-fold higher maximum plasma concentration (C max) and bioavailability (AUC 0→∞) than pure CEL in a dose-linear manner within the dose range of 5–50 mg/kg CEL (R2 > 0.8). Lipolysis drug phase partition data indicate a 2.5–7.5-fold higher CEL solubilising capacity resulting from the digestion of SLH microparticles as compared to the simulated fasted state endogenous micelles. Strong correlations were obtained between maximum CEL solubilisation levels during lipolysis and in vivo pharmacokinetic parameters (R2 > 0.9).
Collectively, the results highlight the potential of the SLH microparticles in enhancing the bioavailability of CEL in a dose-linear manner as facilitated by supersaturated solubilisation of CEL in the intestinal milieu.
KEY WORDScelecoxib dose-dependent absorption in vitro-in vivo correlations lipid-based formulation lipolysis
The authors would like to thank Miss Kathy Lee (Monash Institute of Pharmaceutical Sciences) for technical support on the lipolysis work and Dr. Mihail Popescu (Ian Wark Research Institute) for useful discussion. Financial support of the Australian Research Council, Bio Innovation SA and Itek Pty. Ltd. are also gratefully acknowledged.
- 1.US Food and Drug Administration. Celebrex® (celecoxib) capsules; 1998 December 31. Available from http://www.fda.gov/cder/foi/label/2005/020998s018,019lbl.pdf.
- 2.US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-Inflammatory drugs (NSAIDs); 2005 July 4. Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm.
- 3.Australian Therapeutic Goods Administration. Medicines Regulator cancels registration of anti-inflammatory drug, Lumiracoxib (Prexige); 2007 August 11. Available from http://www.tga.gov.au/media/2007/070811-lumiracoxib.htm.
- 22.Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm. Sci. 2009;98(8):2549–72.Google Scholar
- 24.Adeyeye MC, Brittain HG. Preformulation in solid dosage form development. New York: Informa Healthcare; 2008.Google Scholar
- 26.Schoenwald RD, editor. Pharmacokinetics in drug discovery and development. Boca Raton: CRC; 2002.Google Scholar
- 29.Puranajoti P, Patil RT, Sheth PD, Bommareddy G, Dondeti P, Egbaria K. Design and development of topical microemulsion for poorly water-soluble antifungal agents. J Appl Res. 2002;2(1):XXVII–XXVIII.Google Scholar
- 33.Dressman JB, Lennernas H. Oral drug absorption: prediction and asessment. New York: Marcel Dekker; 2000.Google Scholar
- 38.Friedman MI, Ramirez I, Tordoff MG. Gastric emptying of ingested fat emulsion in rats: implications for studies of fat-induced satiety. Am J Physiol - Reg I. 1996;270(3 39-3):R688–R92.Google Scholar